Melum, E; Franke, A; Schramm, C et al.
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility lociNATURE GENETICS. Bd. 43. H. 1. 2011 S. 17-19
Moehler, M; Al-Batran, SE; Andus, T et al.
German S3-Guideline "Diagnosis and Treatment of Esophagogastric Cancer"ZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 49. H. 4. 2011 S. 461-531
Bruns, H; Watanpour, I; Gebhard, MM et al.
Glycine and Taurine Equally Prevent Fatty Livers from Kupffer Cell-Dependent Injury: An In Vivo Microscopy StudyMICROCIRCULATION. Bd. 18. H. 3. 2011 S. 205-213
Karch, HW; Gockel, I; Goetz, M et al.
Granular-cell tumor (Abrikossoff's tumor): precise preoperative diagnosis is crucial when for minimally-invasive resectionDEUTSCHE MEDIZINISCHE WOCHENSCHRIFT. Bd. 136. H. 31-32. 2011 S. 1609-1612
Bornscheuer, T; Allweiss, L; Volz, T et al.
HEPATITIS B VIRUS INFECTION INHIBITS INTERFERON INDUCED NUCLEAR STAT-1 TRANSLOCATION AND ACTIVATION OF GENES OF THE INNATE RESPONSE IN HUMAN HEPATOCYTES IN CHIMERIC UPA MICEJOURNAL OF HEPATOLOGY. Bd. 54. 2011 S. S39-S39
Lutgehetmann, M; Bornscheuer, T; Volz, T et al.
Hepatitis B Virus Limits Response of Human Hepatocytes to Interferon-alpha in Chimeric MiceGASTROENTEROLOGY. Bd. 140. H. 7. 2011 S. 2074-U310
Schattenberg, JM; Kohl, T; Nagel, M et al.
HEPATOCYTE-SPECIFIC DELETION OF CFLIP ENHANCES LIVER INJURY FROM STREPTOZOTOCIN-INDUCED HYPERGLYCEMIA INVOLVING ACTIVATION OF JNKJOURNAL OF HEPATOLOGY. Bd. 54. 2011 S. S271-S272
Agostoni, A; Aygoren-Pursun, E; Binkley, KE et al.
Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyondJ Allergy Clin Immunol. Bd. 114. H. 3. 2011 S. S51-31
Heuer, AJ; Gehl, A; Puschel, K et al.
HIGH RATE OF CARDIAC ABNORMALITIES IN A POST-MORTEM ANALYSIS OF PATIENTS SUFFERING FROM LIVER CIRRHOSISJOURNAL OF HEPATOLOGY. Bd. 54. 2011 S. S69-S69
Zeuzem, S; Asselah, T; Angus, PW et al.
HIGH SUSTAINED VIROLOGIC RESPONSE FOLLOWING INTERFERON-FREE TREATMENT OF CHRONIC HCV GT1 INFECTION FOR 4 WEEKS WITH HCV PROTEASE INHIBITOR BI201335, POLYMERASE INHIBITOR BI207127 AND RIBAVIRIN, FOLLOWED BY BI201335 AND PEGIFN/RIBAVIRIN - THE SOUND-C1 STUDYHEPATOLOGY. Bd. 54. 2011 S. 486A-487A